Pay in 4 interest-free payments of $5.81 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
In 1993, a Croatian pharmaceutical company called PLIVA licensed it and ran a human clinical trial
Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy
It helps improve skin firmness, regulate melanin, replenish hydration, and reduce dullness
Evaluation of quantitative biosensor for glucose-6-phosphate dehydrogenase activity detection
[12] Disclaimer: The products mentioned are not intended for human or animal consumption
This trial enrolled 100 patients who were randomized to 12 weeks of adalimumab 40 mg every other week or placebo
US$ 26.68
US$ 29.79
US$ 27.12
US$ 26.54
US$ 29.09
US$ 28.26
US$ 21.94
US$ 26.20
US$ 29.80
US$ 29.32
